Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

3.7K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.7K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.4K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.4K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

2.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.6K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.2K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.2K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

3.4K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.4K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Botulinum Toxin Type A Injections in the Bladder Wall-An Effective Treatment for Urinary Incontinence with Low Long-Term Adherence.

Toxins·2026
Same author

Letter regarding Pini, A., Nardini, P., Zizi, V., Molino, M., Calvani, M., Carrozzo, F., … Filippi, L. (2026). β3-adrenoceptor agonism exerts lung protection in a rat model of bronchopulmonary dysplasia. Br J Pharmacol, in press.

British journal of pharmacology·2026
Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025
Same author

Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes.

World journal of urology·2025
Same author

A Comprehensive Review and Meta-analysis on the Treatment of Acute Gastroenteritis in Children with a Bacillus clausii Preparation (Enterogermina<sup>®</sup>).

Advances in therapy·2025
Same author

A Comprehensive Review of the Effects of Hyoscine Butylbromide in Childhood.

Journal of clinical medicine·2025

相关实验视频

Updated: Jan 6, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.1K

在β-腺受体亚型中偏差激进主义:药物开发前景.

Martin C Michel1, Ongun Onaran2

  • 1Department of Pharmacology, University Medical Center, Johannes Gutenberg University, Mainz, Germany. marmiche@uni-mainz.de.

Handbook of experimental pharmacology
|September 13, 2025
PubMed
概括

实现药物选择性对于最小化副作用至关重要. 偏差激进主义为功能性标选择性提供了潜力,但其在药物开发中的应用仍然是复杂和具有挑战性的.

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 药物开发 药物开发
  • 分子生物学分子生物学

背景情况:

  • 药物选择性旨在最大限度地提高所需的治疗效果,同时最大限度地减少不良副作用.
  • 传统的选择性策略包括目标特异性,药理动力学和差异性组织疗效.
  • 偏差激动性,其中一个连接体优先激活一个信号通路而不是其他信号通路,呈现出一种更细微的方法.

研究的目的:

  • 探索药物开发中偏见激进主义的概念和挑战.
  • 了解偏见激进主义在实现功能性目标选择性方面的作用.
  • 评估识别和利用偏向的连接体配置文件以获得治疗效益的复杂性.

主要方法:

  • 对现有关于偏见性激励和药物选择性的文献的审查.
  • 分析评估连接物偏差的复杂性,特别是对于β-腺受体.
  • 讨论在药物研究早期确定所需偏见配置文件的挑战.

主要成果:

  • 偏见激进主义是一种复杂的现象,很难准确评估.
  • 贝塔上腺受体作为研究偏向激进主义的关键模型,但研究结果往往是不确定的.
  • 目前评估偏差信号的方法对药物开发构成重大挑战.
关键词:
有偏见的激进主义.药物开发 药物开发这是一个β1-adrenoceptor.这是一个β2-adrenoceptor.这是一种β3-上腺受体.

更多相关视频

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.4K
Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of &#946;2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

2.3K

相关实验视频

Last Updated: Jan 6, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.1K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.4K
Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of &#946;2 Integrin Activation
04:15

Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation

Published on: February 2, 2024

2.3K

结论:

  • 偏差激进主义在药物设计中增强功能标选择性方面具有前景.
  • 评估中的重大复杂性阻碍了在药物发现中使用偏见激进主义的前景.
  • 需要进一步的研究来克服这些挑战,并有效地利用偏见激进主义.